Pfizer Taps Kyowa Hakko Kirin For New Cancer Combo Study
This article was originally published in PharmAsia News
Executive Summary
Pfizer has chosen Japan's Kyowa Hakko Kirin (KHK) as its latest partner to investigate an immunotherapy approach to cancer through a joint study for a combination of their respective novel monoclonal antibodies.